Consolidation durvalumab

Phase 3Monoclonal antibody

Consolidation durvalumab is one of 5 small molecule programs targeting Non-small Cell Lung Cancer Stage III. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung Cancer Stage IIIRecruiting

Non-Small Cell Lung Cancer Stage IIIPhase 3

Recruiting

Competition

Competitive Landscape

4 competitors in Non-Small Cell Lung Cancer Stage III

#DrugCompanyPhaseTrials

Tagrisso

AstraZeneca

Phase 3

2 2

Imfinzi

AstraZeneca

Phase 2

1 3

Navmi

LIBTAYO

1 5

Consolidation durvalumab

IIdris Bahce

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

ApprovedRecruiting

Non-Small Cell Lung Cancer Stage III

NCT06908070

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer

Terminated·RRachel Sanborn·Phase 2·NCT04364048·10 enrolled

Non-small Cell Lung Cancer Stage III1 trial

ChemoRadiOtherapy With Surgery Followed by Consolidation Durvalumab for Initially Unresectable Stage III NSCLC (CROWD): a Phase IV Feasibility Trial

Recruiting·IIdris Bahce·Approved·NCT06908070·38 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Consolidation durvalumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Consolidation durvalumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Consolidation durvalumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Idris Bahce company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: IIdris Bahce

Consolidation durvalumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Non-small Cell Lung Cancer Stage III1 trial

References

Drug Info

Quick Facts

Related News